The Hypercholesterolemia Market size is estimated to reach $312.3 million by 2027, growing at a CAGR of 5.4% during the forecast period 2022-2027. Hypercholesterolemia is a condition represented by soaring cholesterol amassing in the body. Investigations have constantly recorded that hypertension and hypercholesterolemia repeatedly coexist, bringing about what is termed dyslipidemic hypertension (DH). The hazard of cardiovascular disease (CVD) connected with concomitant hypertension and dyslipidemia is more multiplicative than the total of the individual risk factors. This has been acknowledged in the current treatment guidelines that accentuate the requirement to quantify the complete Cardiovascular Disease (CVD) risk of a person. The terms hyperlipidemia and hypercholesterolemia are frequently utilized interchangeably. However, the two conditions are distinct, in spite of having a certain overlap. Hyperlipidemia is an umbrella term that indicates any of numerous acquired or genetic disorders that lead to a soaring level of lipids - fats, cholesterol and triglycerides - flowing in the blood.
Though hypercholesterolemia itself is asymptomatic, the longstanding boost of serum cholesterol can result in atherosclerosis (hardening of arteries). Over a course of decades, raised up serum cholesterol adds to the formation of atheromatous plaques in the arteries. This can result in progressive contraction of the involved arteries. Type IV hyperlipoproteinemia is the most typical form of hyperlipidemia, marked by hypertriglyceridemia and moderate hypercholesterolemia. It involves numerous genetic ailments of lipid metabolism. However, it is more frequently secondary to another ailment. The increasing predominance of heart ailments, formation of atheromatous plaques in the arteries and unhealthy eating habits are set to drive the Hypercholesterolemia Market. The proliferating count of smokers across the world is set to propel the growth of the Hypercholesterolemia Industry during the forecast period 2022-2027. This represents the Hypercholesterolemia Industry Outlook.
Inquiry Before Buying : https://www.industryarc.com/reports/request-quote?id=17462
Hypercholesterolemia Market Report Coverage
The “Hypercholesterolemia Market Report - Forecast (2022-2027)” by Industry ARC, covers an in-depth analysis of the following segments in the Hypercholesterolemia Market.
by Drug Class : Statins, Niacin, Bile-Acid Resins, Fibric Acid Derivatives, Cholesterol Absorption Inhibitors.
by End-use Industry : Hospitals And Clinics, Ambulatory Surgical Centers, Diagnostic Centers, Research Institutes and Others.
by Geography : North America (the U.S, Canada and Mexico), Europe (Germany, France, the UK, Italy, Spain, Russia and the Rest of Europe), Asia-Pacific (China, Japan, South Korea, India, Australia & New Zealand and the Rest of Asia-Pacific), South America (Brazil, Argentina, Chile, Colombia, Rest of South America) and the Rest of the World (the Middle East and Africa).
Key Takeaways
- Geographically, North America (Hypercholesterolemia market share) accounted for the highest revenue share in 2021 and it is poised to dominate the market over the period 2022-2027, owing to the surging intake of foods soaring in saturated fats and the increasing predominance of dyslipidemia resulting in cardiovascular diseases in the North American region.
- Hypercholesterolemia market growth is being driven by the inactive lifestyle with the dearth of exercise, the rising pervasiveness of dyslipidemia resulting in cardiovascular diseases and the increasing stress and hormones like cortisol raising the FDI Cholesterol Level. However, the rising awareness among the population about fitness and health is one of the major factors hampering the growth of the Hypercholesterolemia market.
- Hypercholesterolemia Market Detailed Analysis of the Strength, Weaknesses and Opportunities of the prominent players operating in the market will be provided in the Hypercholesterolemia Market report.
Hypercholesterolemia Market: Market Share (%) by Region, 2021
Request for Sample : https://www.industryarc.com/pdfdownload.php?id=17462
Hypercholesterolemia Market Segment Analysis - by Drug Class
The Hypercholesterolemia Market based on drug class can be further segmented into Statins, Niacin, Bile-Acid Resins, Fibric Acid Derivatives and Cholesterol Absorption Inhibitors. The statins segment held the largest Hypercholesterolemia market share in 2021. This growth is owing to the increasing application of statins for the treatment of Hypercholesterolemia. Statins are the preferred treatment and best-recognized drug therapy against hypercholesterolemia. Clinicians have long utilized statin medicines for the treatment of hypercholesterolemia, hyperlipoproteinemia and hypertriglyceridemia as an adjunct to diet and exercise. The principal application of these agents is for the primary and secondary prevention of coronary artery disease. The surging application of medications like simvastatin and atorvastatin is further propelling the growth of the Statins segment.
Furthermore, the statins segment is estimated to grow with the fastest CAGR of 6.4% during the forecast period 2022-2027, owing to the benefits of the application of statins for lowering cholesterol and their connection with a reduced hazard of heart ailment and stroke.
Hypercholesterolemia Market Segment Analysis - by End-use Industry
The Hypercholesterolemia Market based on the end-use industry can be further segmented into Hospitals And Clinics, Ambulatory Surgical Centers, Diagnostic Centers, Research Institutes and others. The Hospitals And Clinics Segment held the largest Hypercholesterolemia market share in 2021. This growth is owing to the surging application of hospitals and clinics for the treatment of Hypercholesterolemia. Patients with hypercholesterolemia are cautioned to alter their diet and occupy themselves with regular physical activity. The terms hyperlipidemia and hypercholesterolemia are repeatedly used interchangeably. However, the two conditions are distinct. The existence of progressive infrastructure and skilled physicians in hospitals and clinics are further propelling the growth of this segment.
The Diagnostic Centers segment is estimated to grow with the fastest CAGR of 6.8% during the forecast period 2022-2027, owing to the increasing count of blood tests for detecting increased cholesterol levels in patients in diagnostic centers.
Hypercholesterolemia Market Segment Analysis - by Geography
The Hypercholesterolemia Market based on geography can be further segmented into North America, Europe, Asia-Pacific, South America and the Rest of the World. North America (Hypercholesterolemia Market) held the largest Hypercholesterolemia market share with 39% of the overall market in 2021. The growth of this region is owing to the rising pervasiveness of heart ailments and connected ailments in the North American region. An atheroma, or atheromatous plaques ("plaque"), indicate an abnormal buildup of material in the inner layer of the wall of an artery. The existence of key players like AbbVie Inc in the U.S. is further propelling the growth of the Hypercholesterolemia Industry, thereby contributing to the Hypercholesterolemia Industry Outlook in the North American region.
Furthermore, the Asia-Pacific region is estimated to be the region with the fastest CAGR over the forecast period 2022-2027. This growth is owing to factors like the enormous patient pool in countries like India and China in the Asia-Pacific region. The burgeoning government initiatives and the rising pervasiveness of dyslipidemia are further fuelling the progress of the Hypercholesterolemia Market in the Asia-Pacific region.
Hypercholesterolemia Market Drivers
Increasing Predominance of Hypercholesterolemia in Diabetes is Projected to Drive the Growth of Hypercholesterolemia Market
Dyslipidemias can influence any lipid parameter, inclusive of LDL cholesterol levels, HDL cholesterol levels, triglycerides or integration of these lipids. When only cholesterol levels are soaring or low, this is termed hypercholesterolemia or hypocholesterolemia, respectively. Atheromatous plaques (atheromas) can develop on the intima of large- and medium-caliber arteries. The predominance of hypercholesterolemia, as per the guidelines of the National Cholesterol Education Program, has been decided in a national survey of diabetes and glucose intolerance in the U.S. population. Rates of raised total cholesterol in people with diabetes in the U.S. are only slightly more than in those without diabetes subsequent to adjusting for age and sex. However, soaring or borderline high total cholesterol is typical in diabetes and is existing in 70% of mature grown-ups with diagnosed diabetes and 77% with undiagnosed diabetes in the U.S. population. Among these individuals, 95% have proof of coronary heart disease or two or more risk factors for heart disease and need to therefore have their low-density lipoprotein (LDL) cholesterol assessed. Based on the national data, LDL cholesterol levels calling for dietary treatment for hypercholesterolemia would be anticipated in 85% of these people. The increasing predominance of Hypercholesterolemia in Diabetes is therefore fuelling the growth of the Hypercholesterolemia Market during the forecast period 2022-2027.
Rising Pervasiveness of Obesity is Expected to Boost the Growth of the Hypercholesterolemia Industry
As per the World Health Organization (WHO), 39 million children aged under 5 were overweight or obese in 2020. High cholesterol can influence anyone, regardless of their weight. However, having a surplus body weight can result in raised cholesterol levels. Obesity and soaring cholesterol are both risk factors for cardiovascular health issues. Cholesterol is a waxy substance that the body requires to operate correctly. Hyperlipidemia is a condition that includes different genetic and acquired disorders that depict raised-up lipid levels within the human body. Hyperlipoproteinemia is a typical ailment that appears from an inability to break down lipids or fats in the body, particularly cholesterol and triglycerides. There are numerous kinds of hyperlipoproteinemia. The kind relies on the concentration of lipids and which are influenced. As per the American Heart Association (AHA), high cholesterol can influence people of any weight. However, being overweight may increase the hazard of high cholesterol by causing LDL cholesterol levels to raise and HDL levels to diminish. The rising pervasiveness of obesity is therefore driving the growth of the Hypercholesterolemia Industry, thereby contributing to the Hypercholesterolemia Industry Outlook during the forecast period 2022-2027.
Hypercholesterolemia Market Challenge
Challenges of Inspecting Hypercholesterolemia are Hampering the Growth of the Hypercholesterolemia Market
1 in 200-500 people have Familial Hypercholesterolemia (FH) worldwide. FH may be discovered as repeatedly as 1 in every 67 people in some populations, inclusive of French Canadians, Ashkenazi Jews, Lebanese and South African Afrikaners. Hypercholesterolemia is a tricky ailment to handle. There's still debate regarding the threshold at which active intervention is required. This is specifically true when the lipid profile is only slightly raised up. High cholesterol levels can ultimately result in health conditions like cardiovascular disease. However, how much attention needs to be spent on it, specifically when there are additional comorbidities that demand more immediate attention, is a more important question. The proof requires physicians to at least advise patients on the benefits of exercise, dietary modifications and smoking cessation in attending to the issue. There is still no extensive consensus with regards to if and when a statin needs to be begun. Opinions range from it being a suitable prophylactic drug even in healthy individuals to recommendations that it only be begun in high-risk patients. In practice, doctors rarely inspect the causes of hypercholesterolemia. Rare causes like lysosomal acid lipase deficiency (LAL-D) rarely cross are considered. These issues are thus hampering the growth of the Hypercholesterolemia Market.
Buy Now : https://www.industryarc.com/purchasereport.php?id=17462
Hypercholesterolemia Industry Outlook
Novel product launches, mergers and acquisitions, alliances and R&D activities are key strategies adopted by players in the Hypercholesterolemia Market. The top 10 companies in the Hypercholesterolemia market are:
- AbbVie Inc.
- AstraZeneca Plc
- Amgen Inc.
- Eli Lilly and Company
- Merck & Co.
- Novartis AG
- Pfizer Inc.
- Tekmira Pharmaceuticals Corporation
- Sanofi S.A.
- Cipla Inc.
Recent Developments
- In April 2022, AstraZeneca’s AZD8233 demonstrated positive outcomes for Hypercholesterolemia. AZD8233, an investigational antisense oligonucleotide (ASO), fit the primary endpoint at 50 mg with a 73% reduction in low-density lipoprotein cholesterol (LDL-C) levels from baseline in the ETESIAN phase 2b trial, pronounced by AstraZeneca in a statement. The firm introduced the outcomes from the ETESIAN phase 2b trial at the American College of Cardiology’s 71st Annual Scientific Session.
- In October 2021, AbbVie pronounced that it was preparing to introduce products in India from its global portfolio by the end of 2023 or early 2024 to fit unmet medical requirements against ailments like leukemia, psoriasis, eczema and Alzheimer's. Additionally, the drug maker is also contemplating making India a portion of its worldwide Phase-3 clinical trials for possible therapies under development. This would assist the firm decrease the time to market.
- In June 2021, AbbVie declared that novel data on upadacitinib (RINVOQ®) in ulcerative colitis and risankizumab (SKYRIZI®) in Crohn's disease would be introduced as oral presentations at the 16th Congress of European Crohn's and Colitis Organisation (ECCO), to be held virtually on July 2-3 and July 8-10. AbbVie was supposed to introduce a total of nine abstracts, five of which were oral presentations, across an extensive series of investigations into inflammatory bowel diseases (IBD). Two independent oral presentations would highlight data from the pivotal Phase 3 induction investigations assessing the efficiency and security of upadacitinib (45 mg, once daily) as induction therapy in patients with moderate to severe ulcerative colitis. This concludes the Hypercholesterolemia Industry Outlook.
Relevant Reports:
Report Code: HCR 15172
Report Code: HCR 0314
Report Code: HCR 1211
For more Lifesciences and Healthcare Market reports, please click here
